GlassScriptPhysician profile
Ian Michael Haas
NPI 1013568849
$5,296.96
in general payments reported to CMS, 2019-2025
15 companies · $3,530 in 2025
The $3,530 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $257 · 2023: $306 · 2024: $1,003 · 2025: $3,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085 · Travel and Lodging: $1,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,085.05 |
| Travel and Lodging | $1,753.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $3,016.27 | 2024-2025 | Atricure Cryoice Cryoablation System (Cryo2), Atricure Cryoice Cryosphere Cryoablation System |
| Zimmer Biomet Holdings, INC. | $852.69 | 2025 | Ribfix Titan, Ribfix Blu Advantage, Advantagerib |
| Davol INC. | $531.64 | 2023-2025 | Progel Applicator Spray Tips, Phasix Mesh, Arista Ah Flexitip |
| Progenics Pharmaceuticals, INC. | $347.16 | 2021-2022 | |
| Getinge USA Sales, LLC | $119.20 | 2025 | Vasoview Hemopro 2 |
| Glaxosmithkline, LLC. | $74.91 | 2023 | |
| Sumitomo Pharma America, INC. | $59.35 | 2023 | Orgovyx |
| Janssen Biotech, INC. | $51.59 | 2022-2023 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $44.55 | 2022-2023 | |
| Urovant Sciences INC | $43.28 | 2022 | |
| Antares Pharma, INC. | $37.98 | 2021-2023 | Nocdurna, Xyosted, Tlando |
| Edwards Lifesciences Corporation | $36.90 | 2025 | Mitris Resilia Mitral Valve |
| Teleflex LLC | $29.87 | 2023 | Urolift |
| Astellas Pharma US INC | $28.50 | 2023 | Myrbetriq |
| Merck Sharp & Dohme LLC | $23.07 | 2024 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Haas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.